Genmab — Januar 2025
-
Genmab
@GenmabDuring this edition of #AntibodyHour , Monika Jun, Senior Director, US CORE, shares more on our data-driven approach which helps us identify how we can make the greatest impact on patients. https://x.com/Genmab/status/1882080974449901879
-
Fra intet bud til et bud, på blot 2 min
-
@Nohope: Nu lever du sandelig op til dit navn!

-
-
Johnson & Johnson (JNJ) Q4 2024 Earnings Call Transcript https://www.fool.com/earnings/call-transcripts/2025/01/22/johnson-johnson-jnj-q4-2024-earnings-call-transcri/
-
"So, multiple myeloma is really an extraordinary franchise for us. And maybe I will start with Darzalex because our quarter was over 3 billion. It was 3.1 billion and 22% growth, and we continue to really build out share across, you know, the front-line settings in both transplant-eligible and ineligible patients and in triplet and quad regimens.
-
Darza royalty ender på ca. 800 mio. kr. over budgettet som Genmab startede med i februar 2024. Det er 800 mio. som kommer "igen" årligt indtil 2030 plus årsvæksten der måtte tilgå (uden renters rente og risiko-vurdering), så er NAV Darza, øget med 100 kurspoint på 11 måneder
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind